Permanent Capital Ventures Raises $200M Fund II for Applied AI

TL;DR: Permanent Capital Ventures just launched a $200 million Fund II, pushing total capital raised since its early-2024 founding past $350 million. The firm bets on a narrow thesis: back Series A applied-AI companies and hand them the enterprise sales machinery that a 2026 valuation environment now demands. I think the model is smart and the market it's entering is brutally expensive.

According to Pulse 2.0, Permanent Capital Ventures formally launched on August 27, 2026, disclosing more than $350 million raised since its 2024 inception and confirming that PCV Fund II, a $200 million vehicle, is now actively deploying capital into Series A applied-AI companies. That is not a small fund. It is also not a fund built to spray money across a wide portfolio. PCV runs on a model where each partner makes one to two investments a year, full stop. I want to walk you through what this fund actually does, why the timing matters more than the headline number, and what you should check before you consider an LP stake in a vehicle built this way.

Who's Behind the Check

Permanent Capital Ventures was co-founded by Mike Gamson and Jason Duboe. Gamson spent 11 years at LinkedIn, eventually running its global sales organization while the company's revenue grew from roughly $10 million to $5 billion, through an IPO and the Microsoft acquisition, according to Pulse 2.0. He later ran legal-tech company Relativity and AI-biotech company Evozyne as CEO. Duboe came up through institutional venture at Summit Partners and Chicago Ventures, then joined supply-chain software company project44 as Chief Growth Officer after leading the Chicago Ventures investment in it. He helped take project44 from roughly $1 million to $130 million in annual recurring revenue. Here is why that pairing matters. Most Series A VCs pick companies and then coach from the boardroom. Gamson and Duboe both built the actual sales function inside a company that scaled. That is a different skill than underwriting a pitch deck. When a portfolio CEO asks how to structure a 15-person enterprise sales team or when to hire a VP of Revenue, PCV's partners have done that job, not just funded someone who did. PCV's own published thesis states the logic directly: early traction comes from founder-led sales, but enterprise scale requires go-to-market machinery that most technical founders have never built. The firm's bet is that AI has made it faster than ever to build a product and harder than ever to build the sales organization behind it. That is the gap PCV says it fills.

Why 1-2 Deals a Year Per Partner Is the Real Story

A $200 million fund that only makes a handful of new investments a year is a concentration bet, not a diversification bet. Portfolio names listed on PCV's own portfolio page include Lyric, Recur, Tidalwave, Outmarket AI, Compa, Day AI, Mia Labs, Cynch, TapTap Send, and Provi, along with Logik, which was acquired. That is roughly a decade's worth of Series A relationships for a firm that has existed since early 2024. I have seen plenty of funds claim "high-conviction" investing as a marketing line while still writing 25 checks a year. PCV's stated cadence of one to two investments per team member annually is a real constraint, not a slogan. With two managing partners plus support staff, that likely caps new Fund II positions somewhere in the single digits to low teens over the fund's active investment period. Each check has to be large enough, and each company has to be right enough, to carry real fund-return math. That concentration cuts both ways. If PCV picks the next project44-caliber outcome, LPs do well. If two or three of those concentrated positions stall, the fund has fewer winners to average against the losses. This is the standard venture power-law tension, just sharper than usual because the numerator is smaller.

The Market PCV Is Charging Into

Here is where I get more skeptical. Series A applied-AI investing in 2026 is not cheap, and it is not uncrowded. According to Carta's State of Private Markets report, the median AI company valuation at Series A ran 38% higher than the median non-AI valuation in 2025. That premium exists at every stage from Series A forward, and it gets more extreme as companies mature, reaching a 193% gap by Series E and later. It gets sharper still at the top end. Carta's Q1 2026 data shows AI foundational-model companies raising Series A rounds at a median $300 million valuation, compared with $55 million for non-AI startups at the same stage. Applied-AI companies, PCV's actual target zone, sit somewhere between those two extremes, but the gravitational pull of foundational-model pricing drags the whole category up. More than 60% of all venture capital raised on Carta's platform in Q1 2026 went to AI companies. That is not a niche anymore. That is where the capital is, and where the competition for allocation is fiercest. General Series A pricing has moved too. Carta separately reported the median Series A post-money valuation hit $78.7 million in a recent quarter, up 37% year-over-year from $57.5 million, across all sectors including non-AI. Round sizes are climbing alongside valuations. When PCV writes a Series A check today, it is very likely paying a materially higher entry price than a fund making the same investment in 2023 or 2024. So the real question for a $200 million fund with a handful of new positions a year: is that enough dry powder to build a fund-returning position in an asset class this expensive? A single applied-AI Series A round can now run $30 to $50 million or more when a hot company sets its own terms. If PCV wants meaningful ownership at those prices while reserving capital for follow-on rounds, $200 million gets consumed by a smaller number of companies than the same check size would have bought two years ago. Fund math that worked at 2023 valuations does not automatically work at 2026 valuations. A separate H1 2026 Series A bar report puts a finer point on the competitive pressure: AI captured roughly 81% of global venture deal value in Q1 2026. When four out of every five venture dollars chase AI companies, the bar for what counts as a fundable Series A applied-AI company keeps rising, and so does the price to get an allocation in the ones worth backing.

The Contrarian Case: Operator Value as a Pricing Offset

PCV's counterargument, implicit in its own thesis, is that operator involvement is worth a valuation premium because it changes outcomes, not just optics. If Duboe's team can shave 12 months off the time it takes an applied-AI company to build a repeatable enterprise sales motion, that acceleration can be worth more than the extra points of dilution paid to get PCV's operators in the room. I find that argument credible in principle. I have watched technical founders burn 18 months hiring the wrong VP of Sales, testing the wrong pricing model, or trying to scale outbound before they had a repeatable pitch. That is real value destruction that hands-on operators can prevent. But credible in principle is not the same as proven at scale. PCV is a young firm. Fund I closed in 2024. The oldest positions in the current portfolio are roughly two years old, which is not enough time to see a full venture cycle play out, let alone multiple exits that validate the operator thesis against a control group of companies that raised from generalist funds instead. Acquired portfolio company Logik is a data point, not a track record. I would also flag that "operator-led" is becoming a crowded marketing category across venture right now. Plenty of funds claim hands-on, sales-savvy involvement. What separates a real operator advantage from a pitch deck slide is whether the partners have actually run the function they are advising on, at the scale the portfolio company needs to reach. Gamson and Duboe clear that bar individually. Whether that expertise scales across a dozen simultaneous portfolio companies, each with different products, buyers, and sales cycles, is the open question.

What Accredited Investors Should Check Before an LP Stake

If you are an accredited investor evaluating a direct LP position in a fund built like PCV, either this one or a similar operator-led applied-AI vehicle, check these specifics before you wire capital. Ask for the actual reserve strategy. A concentrated fund needs a real plan for follow-on capital in winners, not just an initial-check strategy. Find out what percentage of the $200 million is earmarked for reserves versus new positions, and ask what happens if a portfolio company needs a bridge round in a down market. Ask how "1-2 investments per partner per year" gets enforced when a great deal shows up outside that cadence. Discipline claims are easy to state and easy to abandon under fear of missing a hot deal. Ask for the actual deployment history across Fund I to see if the stated cadence held. Check the entry valuations PCV paid on its existing portfolio against the Carta benchmarks above. If PCV bought into applied-AI companies at 2024 or early-2025 prices before the premium fully priced in, that is a materially better entry point than paying 2026 prices today. Ask directly what multiple of revenue or what pre-money valuation the fund paid on its five most recent checks. Understand the liquidity timeline. Venture fund LP capital is typically locked for 8 to 10 years or longer. A concentrated fund with a handful of positions has less diversification to smooth a bad exit environment. If two of PCV's core positions do not reach a Series B or beyond, that has a proportionally larger effect on fund returns than it would in a 40-company generalist portfolio. Finally, verify the fund's actual regulatory filings. PCV Fund II, LP appears in SEC Form D filings, which confirms the vehicle exists as a registered private offering. That is baseline diligence, not a signal of quality, but skipping it is not an option.

My Take

I like the operator thesis more than I like the pricing environment PCV is buying into. Gamson and Duboe have real scar tissue from building sales organizations, not just funding them, and that is a genuinely different value proposition than most Series A checks come with. The concentrated, disciplined check-writing cadence is a hedge against the very market conditions Carta's data describes: an environment where the safest strategy is fewer, larger, better-diligenced bets rather than a spray of Series A checks at inflated AI multiples. The risk is straightforward. A firm this young does not have exit data to prove the operator premium pays off, and it is deploying its largest fund yet into a Series A market where AI valuations carry a 30% to 38% premium at minimum, and far more at the top end. If you are considering an LP position, treat the operator pedigree as a real edge and the pricing environment as a real headwind, because both of those things are true at the same time.

For more on this, see our related coverage: Socure's $5.2 Billion Growth Round: What the Summit Partners Deal Structure Signals for Late-Stage Private Investors, Kalshi's SEC Form D Reveals $1.12 Billion Raised, 71 Investors, and Why You Probably Can't Get In at the Primary Level.

Frequently Asked Questions

How much has Permanent Capital Ventures raised in total?

More than $350 million since its early-2024 founding, combining a $150 million Fund I with the newly launched $200 million Fund II, according to the firm's own announcement and reporting from Pulse 2.0.

What stage and sector does PCV invest in?

PCV leads Series A rounds exclusively in applied-AI companies, meaning businesses that use AI within a product rather than foundational-model labs building the underlying AI infrastructure itself.

Why does the Series A AI premium matter for this fund?

Carta's data shows AI companies commanded a 38% valuation premium over non-AI peers at Series A in 2025, with foundational-model companies reaching a median $300 million valuation versus $55 million for non-AI startups at the same stage in Q1 2026. Higher entry prices mean PCV's $200 million buys less ownership per dollar than it would have in a cheaper market, which raises the bar for the fund to return capital at scale.

Is a fund with only 1-2 investments per partner per year too concentrated for LPs?

Concentration is a deliberate tradeoff, not an oversight. It can produce outsized returns if the picks are right, but it also means fewer positions to offset a bad outcome. Prospective LPs should ask for the fund's actual reserve strategy and follow-on plan before assuming concentration alone signals quality.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.